Trial reportDiagnostic pathology2010
Differential expression of microRNAs in GH-secreting pituitary adenomas.
Trial report in Diagnostic pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 96 citations in OpenAlex.
- circOMA1 delivered by exosomes regulates DRD2‑mediated prolactinoma resistance.International journal of molecular medicine · 2026Article
- The clinical effects of miR-26a, miR-16, let-7, miR-128a and miR-223 in acromegaly.Irish journal of medical science · 2025Article
- miR-617 interacts with the promoter ofFrontiers in oncology · 2024Article
- Multiomics Approach to Acromegaly: Unveiling Translational Insights for Precision Medicine.Endocrinology and metabolism (Seoul, Korea) · 2023Review
- miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.International journal of molecular sciences · 2023Article
- Exosomal RNAs in the development and treatment of pituitary adenomas.Frontiers in endocrinology · 2023Review
- MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands.International journal of molecular sciences · 2022Review
- Rno_circ_0001004 Acts as a miR-709 Molecular Sponge to Regulate the Growth Hormone Synthesis and Cell Proliferation.International journal of molecular sciences · 2022Article
- Genome wide analysis of circulating miRNAs in growth hormone secreting pituitary neuroendocrine tumor patients' plasma.Frontiers in oncology · 2022Article
- Architects of Pituitary Tumour Growth.Frontiers in endocrinology · 2022Review
- The cAMP-signaling cancers: Clinically-divergent disorders with a common central pathway.Frontiers in endocrinology · 2022Review
- Circulating miR-29c-3p is downregulated in patients with acromegalyTurkish journal of medical sciences · 2021Article
- Review
- An Exploration of Non-Coding RNAs in Extracellular Vesicles Delivered by Swine Anterior Pituitary.Frontiers in genetics · 2021Article
- GH and IGF System: The Regulatory Role of miRNAs and lncRNAs in Cancer.Frontiers in endocrinology · 2021Review
- MiRNAs as Noninvasive Biomarkers and Therapeutic Agents of Pituitary Adenomas.International journal of molecular sciences · 2020Review
- MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior.Journal of endocrinological investigation · 2020Article
- Biomarkers for Liquid Biopsies of Pituitary Neuroendocrine Tumors.Biomedicines · 2020Review
- DNA Methylation Influences miRNA Expression in Gonadotroph Pituitary Tumors.Life (Basel, Switzerland) · 2020Article
- Elevated miR-16-5p induces somatostatin receptor 2 expression in neuroendocrine tumor cells.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study was to (1) identify specific miRNAs in growth hormones (GH)-secreting pituitary adenomas; (2) determine the relationship between the expression of these miRNAs and tumor size, somatostatin analogs treatment, and responsiveness to somatostatin analogs (SSA).
methodsFifteen GH-secreting adenomas patients were treated with lanreotide for 4 months before surgery. Patients with 50% reduction of GH secretion by lanreotide were considered as SSA responders, while patients with less than 50% of GH reduction were considered as SSA nonresponders. We analyzed the miRNAs in 21 GH-secreting pituitary adenomas and 6 normal pituitaries by miRCURY™ LNA array and some differentially expressed miRNAs were validated by quantitative real-time PCR.
resultsFifty-two miRNAs were differentially expressed between GH-secreting pituitary adenomas and normal pituitaries. Differential expression of 9 miRNAs was observed between micro- and macro-adenomas. Thirteen miRNAs were differentially expressed between tumor samples from lanreotide-treated patients and those from lanreotide-untreated patients. Seven miRNAs were differentially expressed between SSA responders or GH nonresponders. Several identified miRNAs may be involved in cell proliferation, apoptosis, cancer development and progression.
conclusionsOur results indicate that altered miRNAs expression is involved in GH-secreting pituitary adenomas transformation, which will shed light on the mechanisms for the treatment of acromegaly by SSA. Identification and characterization of the targets of altered miRNAs genes may elucidate molecular mechanisms involved in the pathogenesis of pituitary adenoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.